Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych TopicsPsychopharmacology — TCAs and heterocyclics

Psych · Psychopharmacology — TCAs and heterocyclics

Tricyclic and heterocyclic antidepressants

Also known as TCAs · Tricyclic antidepressants · Amitriptyline · Nortriptyline · Clomipramine · Imipramine · Dosulepin · Heterocyclic antidepressants · Trazodone · Maprotiline

Exam-exhaustive fellowship monograph on tricyclic and heterocyclic antidepressants — tertiary vs secondary amines, residual indications (MDD, OCD/clomipramine, neuropathic pain, migraine), adult doses, AGNP-style therapeutic plasma levels, ECG and anticholinergic monitoring, fatal toxicity index, full overdose algorithm (QRS, aVR, sodium bicarbonate, avoid list), heterocyclic relatives, MAOI washouts, special populations. FRANZCP-primary, globally tagged.

high20 referencesUpdated 9 July 2026
On this page & tools

Your progress

Saved locally on this device.

Target exams

FRANZCPMRCPsychABPNMD-DNBNEET-SS

Red flags

Suspected TCA overdose with wide QRS, terminal R in aVR, seizures or hypotension — sodium bicarbonate pathway and critical care, not ward observation aloneHigh suicide risk plus large TCA script — treat means access as a treatment error; restrict supply or switch classMAOI plus TCA (or inadequate washout) — never combine; life-threatening crisis riskNew confusion, urinary retention or severe constipation in an older adult on a tertiary amine — anticholinergic toxicity until proven otherwiseRising plasma level after adding a CYP2D6 inhibitor (fluoxetine, paroxetine, bupropion) — toxicity without dose changeDosulepin (dothiepin) on long-term review with ongoing suicide risk — high fatal toxicity index; prefer switch

Your progress

Saved locally on this device.

Target exams

FRANZCPMRCPsychABPNMD-DNBNEET-SS

Red flags

Suspected TCA overdose with wide QRS, terminal R in aVR, seizures or hypotension — sodium bicarbonate pathway and critical care, not ward observation aloneHigh suicide risk plus large TCA script — treat means access as a treatment error; restrict supply or switch classMAOI plus TCA (or inadequate washout) — never combine; life-threatening crisis riskNew confusion, urinary retention or severe constipation in an older adult on a tertiary amine — anticholinergic toxicity until proven otherwiseRising plasma level after adding a CYP2D6 inhibitor (fluoxetine, paroxetine, bupropion) — toxicity without dose changeDosulepin (dothiepin) on long-term review with ongoing suicide risk — high fatal toxicity index; prefer switch

One-line fellowship answer

TCAs remain efficacious antidepressants (amitriptyline ranks strongly in network meta-analysis) but are not routine first-line for uncomplicated MDD because of overdose lethality, anticholinergic and cardiac off-target effects.[1][2][16] Master three exam pillars: indications (residual MDD, clomipramine for OCD, low-dose pain/migraine), levels (trough TDM with classic plasma bands; AGNP strongly supports monitoring), and toxicity (QRS/aVR-guided risk; IV sodium bicarbonate for cardiotoxicity; never MAOI + TCA).[3][11][13][15]

Definition and classification

Tricyclic antidepressants are lipophilic three-ring compounds that inhibit the serotonin transporter (SERT) and/or norepinephrine transporter (NET), with clinically dominant off-target blockade at muscarinic M1, histamine H1, alpha-1 adrenergic receptors, and cardiac fast voltage-gated sodium channels.[7] Heterocyclic and related agents (maprotiline, mianserin, trazodone, nefazodone) share historical antidepressant use with different receptor and toxicity profiles; mirtazapine is often taught adjacent but is covered in detail in the multimodal topic.

Tertiary amines (amitriptyline, imipramine, clomipramine, doxepin, dosulepin/dothiepin, trimipramine) generally carry heavier anticholinergic/sedative burdens and more serotonergic activity (especially clomipramine). Secondary amines (nortriptyline, desipramine, protriptyline) are demethylated metabolites of tertiary parents, typically more noradrenergic and somewhat better tolerated in older adults when a TCA is still chosen.[2][13]

Educational poster of tricyclic scaffold with cardiac sodium channel, ECG wide QRS and receptor icons
Figure 1. TCA core mapTherapeutic monoamine reuptake is inseparable from Na-channel, muscarinic and alpha-1 toxicity — that dual nature drives every exam stem.
Classification of tertiary versus secondary amines and heterocyclic relatives
Figure 2. ClassificationName the amine class first; examiners use it as a proxy for anticholinergic load and metabolite relationships.

Epidemiology and fatal toxicity context

TCAs dominated depression treatment for decades, then receded as first-line agents once SSRIs and related drugs offered comparable class-level efficacy with far lower overdose lethality and better acceptability for many patients.[1][2] Relative mortality and fatal toxicity index analyses repeatedly place classical TCAs — particularly amitriptyline and dosulepin/dothiepin — among the most lethal antidepressants per prescription unit.[8][9][10] Comparative toxicology series also show TCAs produce more coma and cardiotoxicity than SSRIs in overdose, which is exactly why means restriction is part of prescribing, not an optional social afterthought.[14]

Who still receives them: residual treatment-resistant or melancholic pathways, OCD (clomipramine), neuropathic pain and migraine prophylaxis at often sub-antidepressant doses, enuresis in specialised paediatric contexts, and legacy community scripts that need active review.[15][16][8]

Pathophysiology — therapeutic action and toxicity

Therapeutic: SERT/NET inhibition initiates adaptive monoaminergic cascades with delayed clinical antidepressant response over weeks, not hours.[1] Off-target H1 blockade drives sedation and appetite; M1 drives the dry-mouth/constipation/blurred-vision package; alpha-1 drives orthostasis.

Toxic (exam core): Cardiac fast Na-channel blockade slows phase-0 depolarisation → QRS widening, rightward terminal forces (tall R in aVR), risk of ventricular arrhythmia, hypotension and seizures.[3][4][7] Anticholinergic features produce the classic toxidrome (tachycardia, dry flushed skin, mydriasis, ileus, urinary retention, delirium). Alpha-1 blockade worsens vasodilatory shock. Clomipramine adds higher serotonergic load and serotonin toxicity potential when combined with other serotonergic drugs.

Four-panel TCA mechanism including SERT NET sodium channel muscarinic and alpha-1 effects
Figure 3. Mechanism boardIf you can draw the four receptor axes, you can answer both therapeutic side-effect and overdose stems.

Indications — residual but real

Major depressive disorder

Modern RANZCP and CANMAT guidance place SSRIs/SNRIs and other better-tolerated agents ahead of TCAs for most first-line outpatient MDD; TCAs remain efficacious options later in stepped care or when prior response and monitoring capacity justify them.[16][17][18] Cipriani network meta-analysis found amitriptyline among the more efficacious acute treatments, with acceptability trade-offs that match clinical experience of drop-outs from anticholinergic and sedative effects.[1] Anderson meta-analysis: overall SSRI vs TCA efficacy similar, with signals favouring some TCAs in inpatients and for amitriptyline comparisons, but SSRIs better tolerated.[2] Relapse prevention principles for antidepressants generally apply once remission is achieved.[20]

OCD — clomipramine niche

Clomipramine is the classic TCA with the strongest OCD evidence among tricyclics; meta-analysis of serotonin transport inhibitors showed all active agents beat placebo, with clomipramine more effective than the SSRIs compared in that era's synthesis — modern practice still often starts SSRIs for tolerability, then escalates to clomipramine or combination strategies under specialist care.[15]

Pain, migraine, other

Low-dose amitriptyline (commonly 10–75 mg oral at night for neuropathic pain teaching ranges) is used for pain and migraine prophylaxis; these doses are not interchangeable with full antidepressant titration and still carry overdose and anticholinergic risk.[16] Nocturnal enuresis is a historical imipramine niche now largely displaced by safer first-line options outside specialist pathways.

Heterocyclics — indication and hazard notes

  • Maprotiline: NET-leaning tetracyclic; higher seizure risk teaching point.[7][14]
  • Mianserin: alpha-2/5-HT2 related; less classic cardiotoxicity than TCAs in teaching contrasts; blood dyscrasia historical caution.[14]
  • Trazodone: 5-HT2A/alpha-1; used as sleep adjunct; counsel priapism.[14]
  • Nefazodone: hepatotoxicity risk — avoid when safer options exist.[16]
Hub-and-spoke map of modern TCA clinical roles and fatal toxicity warning
Figure 4. Indication mapIndication is never just 'depression tablet' — name the niche and the lethality tax.

Clinical presentation on treatment

Expect delayed mood benefit, early sedation (tertiary more than secondary), dry mouth, constipation, blurred vision, orthostatic dizziness, sexual dysfunction and weight gain.[2] Activation or early suicide-risk window still requires same-day review standards as for other antidepressants. Missed bipolar spectrum presents as switch into mania if the TCA is used as if unipolar depression were certain.[16][10]

Differential traps

Anticholinergic delirium is not "worsening depression." Wide-complex tachycardia is not "anxiety tachycardia." Serotonin toxicity (hyperreflexia, clonus, hyperthermia) must be separated from anticholinergic toxidrome and from NMS. Other Na-channel blockers (flecainide, carbamazepine, diphenhydramine) can mimic TCA ECG patterns.[5][7]

Assessment before and during prescribing

Pre-start checklist: MSE and suicide risk with means access (existing tablets at home), bipolar screen, cardiac history and baseline ECG, falls risk, constipation/BPH/glaucoma history, pregnancy potential, full medication review (CYP2D6 inhibitors, other anticholinergics, QT-prolonging agents).[13][16]

On treatment: orthostatic BP, anticholinergic symptom review, weight, sexual function, mood rating scales, adherence, and deliberate discussion of what to do if mood or self-harm risk escalates.[13][16]

Investigations and therapeutic drug monitoring (levels)

Baseline and safety labs/ECG

Obtain baseline ECG (QRS duration, QTc, conduction blocks), U&E, and other tests guided by comorbidity. Repeat ECG if dose escalates substantially, interacting drugs are added, or cardiac symptoms appear.[13]

Plasma levels — when and what they mean

Unlike most SSRIs, classic TCAs have concentration–response data and AGNP-level recommendation for therapeutic drug monitoring.[11][12][13] Measure trough concentrations at steady state (typically after about five half-lives on a stable dose; many TCAs about 1 week, agent-dependent).[13]

Teaching reference bands (confirm local lab units — ng/mL vs µg/L are numerically equal): Nortriptyline ~50–150 ng/mL; imipramine + desipramine ~175–300 ng/mL; amitriptyline + nortriptyline ~80–200 ng/mL (lab-specific); clomipramine + desmethylclomipramine lab-specific (monitor parent and metabolite). These ranges are AGNP- and classic TDM teaching scaffolds and must be interpreted with the local laboratory method.[11][13]

Perry and colleagues estimated that response rates are substantially higher inside published therapeutic ranges than outside them — levels are a tool for non-response, adherence, interactions and toxicity, not a vanity number.[11] Glassman's imipramine work helped establish that plasma concentration relates to clinical outcome and that fixed milligram doses produce wide interindividual levels.[12] Hiemke AGNP 2017 consensus codifies recommended ranges, laboratory alert levels and recommendation grades for neuropsychopharmacology TDM, with TCAs among agents where monitoring is strongly supported.[13]

Critical exam contrast: in acute overdose, serial ECG (not waiting for a TCA plasma level) drives bicarb decisions; Boehnert showed QRS duration outperforms serum drug level for predicting seizures and ventricular arrhythmias.[3]

Therapeutic plasma ranges and monitoring checklist for TCAs
Figure 5. Levels and monitoringLevels optimise chronic therapy; QRS optimises the crash trolley.

Acute management — overdose resuscitation

TCA overdose remains a high-lethality medical emergency defined by Na-channel cardiotoxicity, anticholinergic and CNS toxicity.[5][7]

Immediate: ABC with early airway protection if coma or seizure risk, IV access, continuous cardiac monitoring, capillary glucose, temperature, serial ECGs, discuss early with toxicology/ED/ICU.[5][19]

ECG risk thresholds (classic teaching): QRS greater than 100 ms — increased seizure risk; QRS greater than 160 ms — high ventricular arrhythmia risk; terminal R in aVR of 3 mm or more (or elevated R/S in aVR) — additional marker of Na-channel toxicity. These thresholds come from Boehnert and Liebelt and remain viva staples.[3][4]

Sodium bicarbonate is the specific intervention for wide-complex cardiotoxicity, ventricular arrhythmia or refractory hypotension: hypertonic sodium load plus alkalinisation reduces Na-channel blockade; aim clinically for QRS narrowing and controlled alkalinisation (commonly taught target pH around 7.45–7.55, avoiding extreme alkalosis).[5][6] Seizures: benzodiazepines. Avoid class Ia/Ic antiarrhythmics, avoid relying on phenytoin for TCA arrhythmia, and avoid flumazenil in mixed overdoses that may unmask seizures.[5][7] Refractory cardiovascular collapse: involve ICU/toxicology for lipid emulsion and advanced support pathways consistent with contemporary poisoning guidance.[19]

Disposition follows local protocol (GEMNet-style observation logic: prolonged monitoring if any ECG abnormality or significant ingestion; do not discharge on a normal single snapshot after large deliberate self-harm).[5]

TCA overdose management algorithm with bicarbonate and avoid list
Figure 6. Overdose algorithmWide QRS → think bicarb first; the avoid list is as examinable as the antidote.

Definitive management — doses, titration, switching

Adult oral dose scaffolds (always individualise; start low in elderly)

DrugTypical adult oral range (depression context)Notes
AmitriptylineStart 25–50 mg at night; titrate toward 75–150 mg/day (max often 150–200 mg/day supervised)Pain doses often 10–75 mg
NortriptylineStart 10–25 mg; usual 50–100 mg/day; max often 150 mg/dayBest TDM scaffolding among common TCAs
ImipramineStart 25 mg; usual 75–150 mg/dayParent + desipramine levels
ClomipramineStart 25 mg; OCD often needs higher gradual titration toward 100–250 mg/day specialist rangesECG and seizure risk awareness
DosulepinAvoid new starts when alternatives existHigh FTI
Individualise all of the above adult oral scaffolds; efficacy exists but tolerability and lethality constrain use.[1][2][8][9][13][16]

Adequate trial: therapeutic dose (level-guided when available) for about 4–6 weeks with adherence checked before declaring failure.[11][16]

Switching: cross-taper with ECG and side-effect vigilance. Never combine with irreversible MAOIs; respect prolonged washouts (classically about 2 weeks after most TCAs before MAOI; longer after agents with long-lived active metabolites as per product information). Adding fluoxetine, paroxetine or bupropion can spike TCA levels via CYP2D6 inhibition — reduce dose and re-level.[13]

Means restriction: small quantities, blister packs, carer administration, lock-box, and document lethality counselling whenever suicide risk is material.[10]

Subtypes and clinical scenarios

  • Inpatient melancholic depression: historical TCA strength; still not automatic if safer intensive options (including ECT pathways) fit better.[2]
  • OCD: clomipramine after or alongside SSRI strategy.[15]
  • Neuropathic pain / migraine: low-dose amitriptyline; separate consent for off-target risks.[16]
  • Legacy dosulepin review: switch unless clear ongoing benefit and risk is tightly managed.[8][9]
  • Trazodone sleep adjunct: counsel priapism; do not assume "safe TCA alternative" without reviewing hypotension and interactions.[14]

Complications and pitfalls

Cardiotoxicity in overdose; therapeutic-dose conduction risk in vulnerable hearts; anticholinergic delirium and urinary retention; severe constipation; orthostatic falls; seizures (maprotiline and overdose); CYP2D6-mediated level spikes; additive anticholinergic or QT polypharmacy; serotonin toxicity with serotonergic combinations (clomipramine high risk).[7][13][14]

Prognosis and disposition

Therapeutic prognosis tracks depression severity, adherence, comorbidity and whether a true therapeutic level was reached.[11][20] Overdose prognosis is ECG- and physiology-guided; early bicarb and airway care change outcomes.[5][6] Stop or switch TCAs when high suicide risk meets free access to a lethal tablet supply, when significant conduction disease appears, or when safer agents can deliver the same goal.[9][10][16]

Special populations

Older adults: prefer secondary amines if a TCA is unavoidable; start very low (for example nortriptyline 10 mg oral); prioritise falls, cognition, constipation and drug interactions.[13][16] Youth: generally not first-line; overdose lethality is decisive.[9][10] Pregnancy/lactation: individualised perinatal psychiatry decision — do not default to TCA nostalgia.[16] Cardiac disease, narrow-angle glaucoma, significant BPH, dementia: relative contraindications or intensified monitoring.[7][13] Hepatic disease: lower doses; avoid nefazodone.[13][16]

Evidence, guidelines and regional deltas

SourceFellowship take-home
Cipriani 2018 NMAAmitriptyline efficacious; acceptability trade-off[1]
Anderson 2000SSRI ≈ TCA efficacy overall; SSRIs better tolerated[2]
Boehnert / Liebelt / GEMNet / BradberryQRS/aVR and bicarbonate dominate OD care[3][4][5][6]
Henry / Buckley / Hawton / WhyteTCAs high relative lethality in overdose[8][9][10][14]
Perry / Glassman / Hiemke AGNPLevels matter for therapeutic use[11][12][13]
Greist 1995Clomipramine strong OCD signal among SERT inhibitors of that era[15]
RANZCP 2020 / CANMAT 2016–2023TCAs not routine first-line MDD; residual and specialist roles[16][17][18]
AHA 2023 poisoning updateLife-threatening Na-channel toxicity pathways including advanced support concepts[19]

ANZ delta: active review of high-FTI agents (dosulepin), small-quantity dispensing under high risk, and toxicology/ED partnership for OD. NICE/APA-aligned teaching: prefer safer first-line antidepressants for uncomplicated MDD; reserve TCAs with monitoring capacity.[8][9][16][5]

Exam pearls

High-yield one-liners

QRS greater than 100 ms → seizures risk; greater than 160 ms → ventricular arrhythmia risk (Boehnert).[3] Terminal R in aVR of 3 mm or more adds predictive value (Liebelt).[4] Bicarbonate first for wide-complex TCA toxicity — not flecainide or amiodarone as the clever antiarrhythmic.[5][6] Levels guide adequacy and chronic safety; ECG guides the overdose minute-to-minute.[3][13] Clomipramine equals most serotonergic common TCA equals OCD niche plus serotonin toxicity risk.[15] Dosulepin equals high fatal toxicity index equals stop-or-justify on every review.[8][9] Never MAOI + TCA.

Exam-safe synthesis

TCAs still work; they still kill in overdose. Prescribe only with a clear indication, a monitoring plan (ECG ± plasma level), and a means-restriction plan — then you can defend the choice in a FRANZCP viva.[1][10][16]

Three stops that save lives

Wide QRS or malignant arrhythmia on TCA → sodium bicarbonate and critical care pathway.[5][6] Any plan to start an MAOI while a TCA is on board (or washout incomplete) → stop and redesign.[16] High suicide risk with a full bottle of amitriptyline or dosulepin at home → treat the bottle as the emergency.[9][10]

References

  1. [1]Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis Lancet, 2018.PMID 29477251
  2. [2]Anderson IM Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability J Affect Disord, 2000.PMID 10760555
  3. [3]Boehnert MT, Lovejoy FH Jr Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants N Engl J Med, 1985.PMID 4022081
  4. [4]Liebelt EL, Francis PD, Woolf AD ECG lead aVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity Ann Emerg Med, 1995.PMID 7618783
  5. [5]Body R, Bartram T, Azam F, Mackway-Jones K Guidelines in Emergency Medicine Network (GEMNet): guideline for the management of tricyclic antidepressant overdose Emerg Med J, 2011.PMID 21436332
  6. [6]Bradberry SM, Thanacoody HK, Watt BE, Thomas SH, Vale JA Management of the cardiovascular complications of tricyclic antidepressant poisoning: role of sodium bicarbonate Toxicol Rev, 2005.PMID 16390221
  7. [7]Kerr GW, McGuffie AC, Wilkie S Tricyclic antidepressant overdose: a review Emerg Med J, 2001.PMID 11435353
  8. [8]Buckley NA, McManus PR Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data BMJ, 2002.PMID 12468481
  9. [9]Henry JA, Alexander CA, Sener EK Relative mortality from overdose of antidepressants BMJ, 1995.PMID 7866123
  10. [10]Hawton K, Bergen H, Simkin S, et al. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose Br J Psychiatry, 2010.PMID 20435959
  11. [11]Perry PJ, Zeilmann C, Arndt S Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response J Clin Psychopharmacol, 1994.PMID 7962678
  12. [12]Glassman AH, Perel JM, Shostak M, et al. Clinical implications of imipramine plasma levels for depressive illness Arch Gen Psychiatry, 1977.PMID 843179
  13. [13]Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 Pharmacopsychiatry, 2018.PMID 28910830
  14. [14]Whyte IM, Dawson AH, Buckley NA Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants QJM, 2003.PMID 12702786
  15. [15]Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis Arch Gen Psychiatry, 1995.PMID 7811162
  16. [16]Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders Aust N Z J Psychiatry, 2021.PMID 33353391
  17. [17]Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments Can J Psychiatry, 2016.PMID 27486148
  18. [18]Lam RW, Kennedy SH, Adams C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder Can J Psychiatry, 2024.PMID 38711351
  19. [19]Lavonas EJ, Akpunonu PD, Arens AM, et al. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning Circulation, 2023.PMID 37721023
  20. [20]Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review Lancet, 2003.PMID 12606176